

## Quality ID #410: Psoriasis: Clinical Response to Systemic Medications

### 2026 COLLECTION TYPE:

MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) CLINICAL QUALITY MEASURE (CQM)

### MEASURE TYPE:

Intermediate Outcome – High Priority

### DESCRIPTION:

Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient- reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.

### INSTRUCTIONS:

#### **Reporting Frequency:**

This measure is to be submitted a minimum of once per performance period for denominator eligible cases as defined in the denominator criteria.

#### **Intent and Clinician Applicability:**

This measure is intended to reflect the quality of services provided for patients with psoriasis vulgaris. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

#### **Measure Strata and Performance Rates:**

This measure contains one strata defined by a single submission criteria.

This measure produces a single performance rate.

#### **Implementation Considerations:**

For the purposes of MIPS implementation, this patient-intermediate measure is submitted a minimum of once per patient during the performance period. The most recent quality data code will be used if the measure is submitted more than once.

#### **Telehealth:**

**TELEHEALTH ELIGIBLE:** This measure is appropriate for and applicable to the telehealth setting. Patient encounters conducted via telehealth using encounter code(s) found in the denominator encounter criteria are allowed for this measure. Therefore, if the patient meets all denominator criteria for a telehealth encounter, it would be appropriate to include them in the denominator eligible patient population. Telehealth eligibility is at the measure level for inclusion within the denominator eligible patient population and based on the measure specification definitions which are independent of changes to coding and/or billing practices.

#### **Measure Submission:**

The quality data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this collection type for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. The coding provided to identify the measure criteria: Denominator or Numerator, may be an example of coding that could be used to identify patients that meet the intent of this clinical topic. When implementing this measure, please refer to the 'Reference Coding' section to determine if other codes or code languages that meet the intent of the criteria may also be used within the medical record to identify and/or assess patients. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

### DENOMINATOR:

All patients with a diagnosis of psoriasis vulgaris and treated with a systemic medication.

**DENOMINATOR NOTE:**

*For this measure, the patient must ONLY be diagnosed with psoriasis vulgaris (L40.0) and no other concurrent psoriasis diagnosis. Therefore, patients meet criteria when they have been diagnosed with psoriasis vulgaris AND are on a systemic medication PRESCRIBED BY THE PROVIDER BEING EVALUATED FOR THE MEASURE.*

*\*Signifies that this CPT Category I code is a non-covered service under the Medicare Part B Physician Fee Schedule (PFS). These non-covered services should be counted in the denominator population for MIPS CQMs.*

**Denominator Criteria (Eligible Cases):**

All patients, regardless of age

**AND**

Diagnosis for psoriasis vulgaris (ICD-10-CM): L40.0

**AND**

Patient encounter during the performance period (CPT or HCPCS): 98000, 98001, 98002, 98003, 98004, 98005, 98006, 98007, 98008, 98009, 98010, 98011, 98012, 98013, 98014, 98015, 98016, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99242\*, 99243\*, 99244\*, 99245\*, 99341, 99342, 99344, 99345, 99347, 99348, 99349, 99350, 99424, 99426, G0438, G0439

**AND**

Patient has been treated with a systemic medication for psoriasis vulgaris: G9764

**Reference Medications:**

Denominator Criteria for **Systemic Medication [G9764]** may be defined by the following examples, however, other medications that meet the intent of this component may also be used:

Examples of Applicable Medications			
Brand Name	Chemical Name	Mechanism Action/ Type of Systemic	Indication
Abrilada	adalimumab-afzb	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Amjevita	adalimumab-atto	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Avsola	infliximab-axxq	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Bimzelx	bimekizumab-bkzx	IL-17 inhibitors	Psoriasis
Cimzia	Certolizumab pegol	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Cosentyx	secukinumab	IL-17 inhibitors	Psoriasis, Psoriatic arthritis
Cyltezo	adalimumab-adbm	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Enbrel	etanercept	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Erelzi	etanercept-szsz	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Gengraf	cyclosporine, modified	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Hadlima	adalimumab-bwwd	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Hulio	adalimumab-fkjp	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Humira	adalimumab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Hyrimoz	adalimumab-adaz	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Idacio	adalimumab-aacf	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Ilumya	Tildrakizumab	Selective (IL)-23p19 inhibitor	Psoriasis
Inflectra	infliximab-dyyb	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Jylamvo	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
Neoral	cyclosporine, modified	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Orencia	abatacept	Blocks T-cell activation	Psoriatic arthritis
Otezla	apremilast	Blocks phosphodiesterase-4	Psoriasis, Psoriatic arthritis

Examples of Applicable Medications			
Brand Name	Chemical Name	Mechanism Action/ Type of Systemic	Indication
		(PDE4)	
Otrexup	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
Pyzchiva	ustekinumab-ttwe	IL-12 and IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Rasuvo	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
RediTrex	methotrexate	Inhibits dihydrofolic acid reductase	Psoriasis
Remicade	infliximab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Renflexis	infliximab-abda	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Rheumatrex	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Rinvoq and Rinvoq LQ	upadacitinib	Inhibits janus-associated kinases (JAK)	Psoriatic arthritis
Sandimmune	cyclosporine	Blocks lymphocytes (T cells) and lymphokines	Psoriasis
Selarsdi	ustekinumab-aekn	IL-12 and IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Skyrizi	risankizumab-rzaa	IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Siliq	brodalumab	IL-17 inhibitors	Psoriasis
Simlandi	adalimumab-ryvk	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Simponi and Simponi Aria	golimumab	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Soriatane	acitretin	Unknown; activates retinoid receptors	Psoriasis
Sotyktu	deucravacitinib	Inhibits tyrosine kinase 2 (TYK2)	Psoriasis
Spevigo	spesolimab-sbzo	IL-36 inhibitors	Pustular Psoriasis
Stelara	ustekinumab	IL-12 and IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Taltz	ixekizumab	IL-17 inhibitors	Psoriasis, Psoriatic arthritis
Tremfya	guselkumab	IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Trexall	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Wezlana	ustekinumab-auub	IL-12 and IL-23 inhibitors	Psoriasis, Psoriatic arthritis
Xatmep	methotrexate	Blocks dihydrofolate reductase	Psoriasis
Xeljanz and Xeljanz XR	tofacitinib	Inhibits janus-associated kinases (JAK)	Psoriatic arthritis
Yuflyma	adalimumab-aaty	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis
Yusimry	adalimumab-aqvh	TNF-alpha inhibitors	Psoriasis, Psoriatic arthritis

#### **NUMERATOR:**

Patients who have a documented physician global assessment (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI) that meet any one of the below specified benchmarks.

#### **Definition:**

**Consecutive Months** – The consecutive treatment allows gaps in the medication treatment up to a total of 4 weeks during the 6 month period. Gaps can include periods in which the patient is changing or refilling medication, but regardless of the number of gaps, the total cannot be for more than 4 weeks.

#### **Numerator Instructions:**

To satisfy this measure, a patient must achieve any ONE of the following:

- PGA (5-point OR 6-point scale)  $\leq 2$  (clear to mild skin disease)
- BSA < 3% (mild disease)
- PASI < 3 (no or minimal disease)
- DLQI  $\leq 5$  (no effect or small effect on patient's quality of life)

**NUMERATOR NOTE:**

*For Denominator Exception(s), patients are ineligible for this measure if at the time of encounter there are patient or medical reason(s) for not meeting specified benchmarks (e.g. patient declined change in medication, patient experience adverse effects, etc.) as further specified below.*

**Numerator Options:****Performance Met:**

Psoriasis assessment tool documented meeting anyone of the specified benchmarks (e.g., (PGA; 5-point OR 6- point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI)) (G9649)

**OR**

**Denominator Exception:**

Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI (G9765)

**OR**

**Performance Not Met:**

Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (PGA; 5-point OR 6-point scale), body surface area (BSA), psoriasis area and severity index (PASI) and/or dermatology life quality index (DLQI)) or psoriasis assessment tool not documented (G9651)

**RATIONALE:**

A significant proportion of psoriasis patients who are receiving treatment remain unsatisfied with their therapies due to various reasons including lack of or loss of efficacy, side effects, and inconvenience, among others. Treatment dissatisfaction also contributes to patients discontinuing their medication. This measure evaluates the proportion of psoriasis vulgaris patients receiving systemic medication who meet minimal physician or patient-reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment.

**CLINICAL RECOMMENDATION STATEMENTS:**

1. Treatment goals (assessment after 10 to 16 weeks, and every 8 weeks thereafter): PASI 75 or PGA of 'clear' or 'almost clear'; or DLQI of 0 or 1 (Pathirana, 2009).
2. Minimum efficiency ('lowest hurdle'): PASI 50; DLQI<5 or improvement by at least 5 points (Pathirana, 2009).
3. Continue therapy if PASI 75 response (or if PASI 50 response and DLQI≤5) (Mrowietz, 2011).
4. Adequate response to treatment is defined as either:
  - a. PASI 50 response (or ≥50% improvement in BSA) and ≥5-point improvement in DLQI; or
  - b. PASI 75 response (Smith, 2009).
5. Treatment 'success' defined as PASI 75 response (or PASI 50 response and DLQI≤5) (Baker, 2013).

**REFERENCES:**

Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. *Australas J Dermatol*. 2013;54(2):148-154.

Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res*. 2011;303(1):1-10

Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol*. 2009;23 Suppl 2:1-70.

Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol*. 2009;161(5):987-1019.

**COPYRIGHT:**

This Measure is not a clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

This Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.

Commercial use of this measure requires a license agreement between the user and the American Academy of Dermatology (AAD). Neither the AAD nor its members shall be responsible for any use of the Measure.

AAD encourages use of this Measure by other health care professionals, where appropriate.

**THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.**


© 2025 American Academy of Dermatology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AAD and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measures specifications is copyright 2004-2025 American Medical Association. LOINC® copyright 2004-2025 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2025 International Health Terminology Standards Development Organisation. ICD-10 is copyright 2025 World Health Organization. All Rights Reserved.

## 2026 Clinical Quality Measure Flow for Quality ID #410: Psoriasis: Clinical Response to Systemic Medications

**Disclaimer:** Refer to the measure specification for specific coding and instructions to submit this measure.



### SAMPLE CALCULATIONS

#### Data Completeness=

Performance Met (a=40 patients) + Denominator Exception (b=10 patients) + Performance Not Met (c=20 patients) = 70 patients = 87.50%  
Eligible Population / Denominator (d=80 patients) = 80 patients

#### Performance Rate=

Performance Met (a=40 patients) = 40 patients = 66.67%  
Data Completeness Numerator (70 patients) – Denominator Exception (b=10 patients) = 60 patients

\*See the posted measure specification for specific coding and instructions to submit this measure.

Note: Submission Frequency: Patient-Intermediate

CPT only copyright 2025 American Medical Association. All rights reserved.  
The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.  
v10

## 2026 Clinical Quality Measure Flow Narrative for Quality ID #410: Psoriasis: Clinical Response to Systemic Medications

*Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.*

1. Start with Denominator
2. *All patients, regardless of age*
3. Check *Diagnosis for psoriasis vulgaris as listed in Denominator\**:
  - a. If *Diagnosis for psoriasis vulgaris as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Diagnosis for psoriasis vulgaris as listed in Denominator\** equals Yes, proceed to check *Patient encounter during the performance period as listed in Denominator\**.
4. Check *Patient encounter during the performance period as listed in Denominator\**:
  - a. If *Patient encounter during the performance period as listed in Denominator\** equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patient encounter during the performance period as listed in Denominator\** equals Yes, proceed to check *Patient has been treated with a systemic medication for psoriasis vulgaris*.
5. Check *Patient has been treated with a systemic medication for psoriasis vulgaris*:
  - a. If *Patient has been treated with a systemic medication for psoriasis vulgaris* equals No, do not include in *Eligible Population/Denominator*. Stop processing.
  - b. If *Patient has been treated with a systemic medication for psoriasis vulgaris* equals Yes, include in *Eligible Population/Denominator*.
6. Denominator Population:
  - Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.
7. Start Numerator
8. Check *Psoriasis assessment tool documented meeting any one of the specified benchmarks*:
  - a. If *Psoriasis assessment tool documented meeting any one of the specified benchmarks* equals Yes, include in *Data Completeness Met and Performance Met*.
    - *Data Completeness Met and Performance Met* letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation.

- b. If *Psoriasis assessment tool documented meeting any one of the specified benchmarks* equals No, proceed to check *Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI*.
  9. Check *Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI*:
    - a. If *Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI* equals Yes, include in *Data Completeness Met and Denominator Exception*.
      - *Data Completeness Met and Denominator Exception* letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 patients in the Sample Calculation.
    - b. If *Documentation that the patient declined change in medication or alternative therapies were unavailable, has documented contraindications, or has not been treated with a systemic medication for at least six consecutive months in order to achieve better disease control as measured by PGA, BSA, PASI, or DLQI* equals No, proceed to check *Psoriasis assessment tool documented not meeting any one of the specified benchmarks or psoriasis assessment tool not documented*.
  10. Check *Psoriasis assessment tool documented not meeting any one of the specified benchmarks or psoriasis assessment tool not documented*:
    - a. If *Psoriasis assessment tool documented not meeting any one of the specified benchmarks or psoriasis assessment tool not documented* equals Yes, include in *Data Completeness Met and Performance Not Met*.
      - *Data Completeness Met and Performance Not Met* letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 patients in the Sample Calculation.
    - b. If *Psoriasis assessment tool documented not meeting any one of the specified benchmarks or psoriasis assessment tool not documented* equals No, proceed to check *Data Completeness Not Met*.
  11. Check *Data Completeness Not Met*:
    - If *Data Completeness Not Met*, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

### **Sample Calculations:**

Data Completeness equals Performance Met (a equals 40 patients) plus Denominator Exception (b equals 10 patients) plus Performance Not Met (c equals 20 patients) divided by Eligible Population/Denominator (d equals 80 patients). All equals 70 patients divided by 80 patients. All equals 87.50 percent.

Performance Rate equals Performance Met (a equals 40 patients) divided by Data Completeness Numerator (70 patients) minus Denominator Exception (b equals 10 patients). All equals 40 patients divided by 60 patients. All equals 66.67 percent.

\*See the posted measure specification for specific coding and instructions to submit this measure.



NOTE: Submission Frequency: Patient - Intermediate

The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.